Article
New paradigms in gastrointestinal stromal tumour management.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 May 2009
Blay J-Y
Abstract excerpt
BACKGROUND: Targeted agents have improved the prognosis for patients with advanced gastrointestinal stromal tumours (GISTs). Many patients exhibit intolerance or resistance to first-line therapy with imatinib mesylate. Sunitinib malate is approved multinationally for the treatment of advanced imatinib-refractory GIST. DESIGN: This article reviews responses to imatinib and sunitinib reported in clinical trials in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
